CTCs
Biocept to Refocus CNSide Assay Plans After FDA Feedback Suggests Targeting Narrower Indications
Premium
The company failed in its first bid for breakthrough device designation but has now split out new specific indications for which it is building more persuasive utility data.
Rarecells Raises $13M in Series A Round to Develop Liquid Biopsy Early Cancer Detection Tests
The company is planning to develop circulating tumor cell assays for prostate cancer and acute myeloid leukemia and to launch them in the US.
The company is embarking on its own diagnostic plans as it prepares to market its platform for external test development following FDA clearance.
The Indian liquid biopsy company recently launched its Trublood tests for prostate cancer and pan-cancer detection using circulating tumor cells.
Capio Biosciences, BioView to Explore Integration of Circulating Tumor Cell Technologies
The companies are conducting a study to evaluate their combined platforms for the detection and characterization of CTCs in prostate cancer.